



261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis

Client Name: Rhize Cannabis Company
License Number: SCLT0295 MANU0065



Sample ID: 20260603-32365
Sample Name: The Hive Flower
Sample Lot: HL-31B
Sample Matrix: Flower
Date Received: 6/4/2026
Date Reported: 6/10/2026
Date Tested: 6/9/2026

Total Cannabinoids

	%	mg/g
Total THC:	22.788	227.885
Total CBD:	--	--
Total Cannabinoids:	27.068	270.683

Total theoretical CBD % = (CBD%) + (CBDA% * 0.877)
Total theoretical THC % = (delta-9-THC%) + (THCA% * 0.877)

Potency

Standard potency analysis utilizing High Performance Liquid Chromatography (HPLC; SOP-102-OA) | Test ID: #106780

Analyte	% (Dry)	mg/g (Dry)	%	mg/g	LOD (mg/g)	LOQ (mg/g)
CBC	ND	ND	ND	ND	0.0003	0.0040
CBCA	< LOQ	< LOQ	< LOQ	< LOQ	0.0002	0.0040
CBD	< LOQ	< LOQ	< LOQ	< LOQ	0.0008	0.0040
CBDA	ND	ND	ND	ND	0.0002	0.0040
CBDV	ND	ND	ND	ND	0.0008	0.0040
CBDVA	ND	ND	ND	ND	0.0001	0.0040
CBG	< LOQ	< LOQ	< LOQ	< LOQ	0.0009	0.0040
CBGA	1.084	10.837	0.958	9.579	0.0001	0.0040
CBN	ND	ND	ND	ND	0.0004	0.0040
CBNA	ND	ND	ND	ND	0.0002	0.0040
D8 THC	ND	ND	ND	ND	0.0012	0.0040
D9 THC	ND	ND	ND	ND	0.0016	0.0049
D10 THC	ND	ND	ND	ND	0.0004	0.0040
THCA	25.985	259.846	22.968	229.678	0.0002	0.0040
THCV	ND	ND	ND	ND	0.0016	0.0049
THCVA	ND	ND	ND	ND	0.0002	0.0040

* Measurements of uncertainty available on request

Moisture & Water Activity

PASS

Water Activity and Moisture Content Analysis (SOP-120-OA) | Test ID: #106781

Analyte	Result (%)	Limit	Pass/Fail
Moisture	11.61	13.00	PASS
Water Activity	0.53	0.65	

Callie Chapman

Callie Chapman
Lab Director
6/10/2026

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.





261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis



Client Name: Rhize Cannabis Company

License Number: SCLT0295 MANU0065



Sample ID: 20260603-32365

Sample Name: The Hive Flower

Sample Lot: HL-31B

Sample Matrix: Flower

Date Received: 6/4/2026

Date Reported: 6/10/2026

Date Tested: 6/9/2026



Total Terpenes (%) : 1.2317

Dominant Terpenes (%)

Limonene	0.3148
Myrcene	0.3066
Linalool	0.1632
beta-caryophyllene	0.1545
alpha-Humulene	0.0768

Terpenes

Standard terpene analysis utilizing Gas Chromatography – Mass Spectrometry (GC-MS; SOP-069-OA) | Test ID: #106782

Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)
3-Carene	ND	ND	0.000002	0.001
alpha-Bisabolol	0.0253	0.253	0.000003	0.001
alpha-Humulene	0.0768	0.768	0.000002	0.001
alpha-Pinene	0.0279	0.279	0.000001	0.001
alpha-Terpinene	ND	ND	0.000001	0.001
alpha-Terpinolene	0.0098	0.098	0.000004	0.001
beta-caryophyllene	0.1545	1.545	0.000004	0.001
beta-Pinene	0.0518	0.518	0.000002	0.001
Camphene	0.0081	0.081	0.000001	0.001
Caryophyllene Oxide	0.0121	0.121	0.000011	0.001
Eucalyptol	ND	ND	0.000002	0.001
gamma-Terpinene	ND	ND	0.000002	0.001
Geraniol	ND	ND	0.000008	0.003
Guaiol	0.0503	0.503	0.000007	0.001
Isopulegol	ND	ND	0.000005	0.001
Isopropyl Toluene	ND	ND	0.000003	0.001
Limonene	0.3148	3.148	0.000002	0.001
Linalool	0.1632	1.632	0.000003	0.001
Nerolidol	0.0305	0.305	0.000007	0.001
Myrcene	0.3066	3.066	0.000003	0.001
Ocimene	ND	ND	0.000002	0.001
Total Terpenes	1.2317	12.317		

Callie Chapman

Callie Chapman
Lab Director
6/10/2026

Rev. 1 Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.





261 Mountain View Dr
Colchester, VT 05446
License #: TLAB0030
802-767-7256
info@onwardanalytics.biz

Certificate of Analysis

Client Name: Rhize Cannabis Company
License Number: SCLT0295 MANU0065

Sample ID: 20260603-32365
Sample Name: The Hive Flower
Sample Lot: HL-31B
Sample Matrix: Flower
Date Received: 6/4/2026
Date Reported: 6/10/2026
Date Tested: 6/5/2026



Pathogens PASS

Microbiological screening utilizing qPCR (SOP-130-OA) | Test ID: #106783

Analyte	Result	Pass/Fail
A. Fumigatus	None Detected	PASS
A. Niger	None Detected	PASS
A. Flavus	None Detected	PASS
A. Terreus	None Detected	PASS
STEC	None Detected	PASS
Salmonella	None Detected	PASS



Callie Chapman
Lab Director
6/10/2026

Rev. 1Initial Release

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

